Oculis Holding AG (OCS) Research & Development (2022 - 2026)

Oculis Holding AG's Research & Development history runs 5 years deep, the most recent figure standing at -$17.9 million for Q1 2026.

• On a quarterly basis, Research & Development fell 9.18% year-over-year to -$17.9 million in Q1 2026; TTM through Mar 2026 was -$17.7 billion, a 17.6% decrease from a year earlier, with the FY2025 full-year figure at -$68.9 million, down 16.3% from the prior year.
• Research & Development retreated to -$17.9 million in Q1 2026 per OCS's latest filing, from -$16.6 million in the prior quarter.
• Across five years, Research & Development topped out at -$4.8 million in Q3 2022 and bottomed at -$17.6 billion in Q3 2025.
• The 5-year median for Research & Development is -$12.9 million (2024), against an average of -$2.1 billion.
• Across the five-year window, Research & Development plunged 149271.33% in 2024 and gained 1.09% in 2025, its largest moves.
• Year by year, Research & Development stood at -$7.2 million in 2022, then decreased by 26.58% to -$9.1 million in 2023, then tumbled by 48.35% to -$13.4 million in 2024, then fell by 23.82% to -$16.6 million in 2025, then dropped by 7.89% to -$17.9 million in 2026.
• Per Business Quant, the three latest OCS Research & Development figures stand at -$17.9 million (Q1 2026), -$16.6 million (Q4 2025), and -$17.6 billion (Q3 2025).